Literature DB >> 1668016

Immune effect of tumor-infiltrating lymphocytes and its relation to the survival rate of patients with ovarian malignancies.

D Ma1, M J Gu.   

Abstract

Tumor-infiltrating lymphocytes (TIL) in histological sections from 94 patients with ovarian malignancies were quantitated for their relation to the prognosis of the patients. It was found that the degree of lymphocyte infiltration directly affected the patients' survival rate and also related to clinical staging of the patients, as well as grading and histologic typing of the tumor. T lymphocytes characterized by alpha-naphthyl acetate (ANAE) staining were the major cells in the stroma of ovarian malignancies. Ultrastructural study of TIL and cancer cells suggested that tumor cell degeneration is related to the effect of TIL.

Entities:  

Mesh:

Year:  1991        PMID: 1668016     DOI: 10.1007/bf02888158

Source DB:  PubMed          Journal:  J Tongji Med Univ        ISSN: 0257-716X


  7 in total

1.  Rapid method for determining T lymphocyte levels using acid alpha-naphthyl acetate esterase.

Authors:  R Giorno; S Beverly
Journal:  Stain Technol       Date:  1981-05

Review 2.  Tumor biology.

Authors:  R M Sutherland; J S Rasey; R P Hill
Journal:  Am J Clin Oncol       Date:  1988-06       Impact factor: 2.339

3.  Prognostic factors in malignant epithelial ovarian tumors.

Authors:  K Sigurdsson; P Alm; B Gullberg
Journal:  Gynecol Oncol       Date:  1983-06       Impact factor: 5.482

4.  In vivo antitumor activity of tumor-infiltrating lymphocytes expanded in recombinant interleukin-2.

Authors:  P J Spiess; J C Yang; S A Rosenberg
Journal:  J Natl Cancer Inst       Date:  1987-11       Impact factor: 13.506

5.  Lymphocytic infiltration and survival in rectal cancer.

Authors:  J R Jass
Journal:  J Clin Pathol       Date:  1986-06       Impact factor: 3.411

6.  Histologic correlates of virulence in ovarian adenocarcinoma. II. Morphologic correlates of host response.

Authors:  L Deligdisch; A J Jacobs; C J Cohen
Journal:  Am J Obstet Gynecol       Date:  1982-12-15       Impact factor: 8.661

7.  A correlation between the expression of CD 8 antigen and specific cytotoxicity of tumor-infiltrating lymphocytes.

Authors:  Y Okada; G Yahata; S Takeuchi; T Seidoh; K Tanaka
Journal:  Jpn J Cancer Res       Date:  1989-03
  7 in total
  7 in total

Review 1.  Tumor infiltrating lymphocytes in ovarian cancer.

Authors:  Phillip P Santoiemma; Daniel J Powell
Journal:  Cancer Biol Ther       Date:  2015-04-20       Impact factor: 4.742

2.  Potential clinical application of tumor-infiltrating lymphocyte therapy for ovarian epithelial cancer prior or post-resistance to chemotherapy.

Authors:  Donastas Sakellariou-Thompson; Marie-Andrée Forget; Emily Hinchcliff; Joseph Celestino; Patrick Hwu; Amir A Jazaeri; Cara Haymaker; Chantale Bernatchez
Journal:  Cancer Immunol Immunother       Date:  2019-10-10       Impact factor: 6.968

3.  Enumeration of leukocyte infiltration in solid tumors by confocal laser scanning microscopy.

Authors:  J Biggerstaff; B Weidow; A Amirkhosravi; J L Francis
Journal:  BMC Immunol       Date:  2006-07-21       Impact factor: 3.615

4.  Regulatory T Cells with Additional COX-2 Expression Are Independent Negative Prognosticators for Vulvar Cancer Patients.

Authors:  Nadine Ansorge; Christian Dannecker; Udo Jeschke; Elisa Schmoeckel; Helene Hildegard Heidegger; Aurelia Vattai; Maximiliane Burgmann; Bastian Czogalla; Sven Mahner; Sophie Fuerst
Journal:  Int J Mol Sci       Date:  2022-04-22       Impact factor: 6.208

5.  The prognostic value of tumor-infiltrating T lymphocytes in ovarian cancer.

Authors:  Jun Li; Jieyu Wang; Ruifang Chen; Yang Bai; Xin Lu
Journal:  Oncotarget       Date:  2017-02-28

Review 6.  Role of tumor microenvironment in ovarian cancer pathobiology.

Authors:  Alia Ghoneum; Hesham Afify; Ziyan Salih; Michael Kelly; Neveen Said
Journal:  Oncotarget       Date:  2018-04-27

7.  Expression of EBAG9/RCAS1 is associated with advanced disease in human epithelial ovarian cancer.

Authors:  J-I Akahira; M Aoki; T Suzuki; T Moriya; H Niikura; K Ito; S Inoue; K Okamura; H Sasano; N Yaegashi
Journal:  Br J Cancer       Date:  2004-06-01       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.